Dyspnea¶
Chapter 39 | Part 2: Cardinal Manifestations and Presentation of Diseases
KEY CLINICAL POINTS¶
- Dyspnea is a subjective experience of breathing discomfort with multiple physiological, psychological, and environmental contributors.
- Chronic dyspnea (lasting >1 month) is common, affecting 9–37% of adults ≥ 70 years, with 85% of cases attributable to pulmonary or cardiac causes.
- The Modified Medical Research Council (MMRC) Dyspnea Scale is a validated tool for assessing dyspnea severity in COPD.
- Differential diagnosis includes pulmonary (airway/parenchymal/costal), cardiac (left/right heart), and non-cardiopulmonary (anemia, deconditioning, psychological) causes.
- Diagnostic algorithm includes history, physical exam, chest imaging, spirometry, and cardiopulmonary exercise testing (CPET) to distinguish respiratory vs. cardiovascular etiologies.
1. DEFINITION & OVERVIEW¶
Dyspnea is a subjective experience of breathing discomfort defined by the American Thoracic Society as a qualitative sensation varying in intensity, influenced by physiological, psychological, social, and environmental factors. It is self-reported and distinct from objective signs of increased work of breathing (e.g., tachypnea, accessory muscle use).
Table 39-1: Modified Medical Research Council Dyspnea Scale¶
| GRADE OF DYSPNEA | DESCRIPTION |
|---|---|
| 0 | Not troubled by breathlessness, except with strenuous exercise |
| 1 | Shortness of breath walking on level ground or with walking up a slight hill |
| 2 | Walks slower than people of similar age on level ground due to breathlessness, or has to stop to rest when walking at own pace on level ground |
| 3 | Stops to rest after walking 100 m or after walking a few minutes on level ground |
| 4 | Too breathless to leave the house, or breathless with activities of daily living (e.g., dressing/undressing) |
1.1 Pathophysiology¶
Dyspnea arises from complex interactions between afferent signals (chemoreceptors, mechanoreceptors, metaboreceptors) and efferent signals from the CNS. Efferent-reafferent mismatch (discrepancy between expected and actual respiratory output) contributes to the sensation.
1.2 Clinical Classification¶
Dyspnea is classified as acute (intermittent episodes) or chronic (persistent). Chronic dyspnea is more common in older adults and often reflects progressive pulmonary/cardiac disease.
2. EPIDEMIOLOGY¶
Dyspnea is common, with up to 50% of inpatients and 25% of ambulatory patients experiencing it. Community prevalence is 9–13%, rising to 37% in adults ≥ 70 years. It accounts for 3–4 million ER visits/year. Post-COVID-19 dyspnea is increasingly prevalent.
2.1 Risk Factors¶
Age ≥ 70 years, male sex, smoking, COPD, heart failure, obesity, and post-COVID-19 syndrome. Periodontal disease and poor oral hygiene contribute to halitosis-related dyspnea.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Dyspnea arises from pulmonary (airway, parenchymal, chest wall), cardiac (left/right heart), and non-cardiopulmonary (anemia, deconditioning, psychological) mechanisms. Key pathophysiological pathways include: 1. Chemoreceptor activation (hypoxemia/hypercapnia) 2. Mechanoreceptor stimulation (airway resistance, lung compliance) 3. Metaboreceptor activation (exercise intolerance) 4. Efferent-reafferent mismatch (CNS-ventilatory system discrepancy)
4. CLINICAL FEATURES¶
Symptoms include chest tightness, air hunger, exertional dyspnea, orthopnea, and nocturnal dyspnea. Signs include tachypnea, accessory muscle use, intercostal retractions, and pulsus paradoxus. Physical findings may include clubbing, cyanosis, and pulmonary hypertension signs.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnosis includes: Pulmonary: Asthma, COPD, interstitial lung disease, pulmonary embolism Cardiac: Left/right heart failure, pericardial disease, pulmonary hypertension Non-cardiopulmonary: Anemia, deconditioning, anxiety, GERD, post-COVID syndrome
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic algorithm (Fig. 39-2): 1. History: Positional changes (platypnea), exertional vs. resting dyspnea, associated symptoms (e.g., wheezing, crackles) 2. Physical exam: Chest symmetry, percussion, auscultation, cardiac exam 3. Initial tests: Chest X-ray, spirometry, ECG, oximetry 4. Advanced tests: Chest CT, CPET, echocardiogram, BNP testing 5. Specialized testing: Bronchoprovocation, pulmonary function tests, ventilation/perfusion scans
Table 39-2: Differential Diagnosis of Disease Processes Underlying Dyspnea¶
| SYSTEM | TYPE OF PROCESS | EXAMPLE OF DISEASE | POSSIBLE P RESENTING SYMPTOMS | POSSIBLE PHYSICAL FINDINGS | MECHANISM S UNDERLYI NG DYSPNEA | INITIAL DIAGNOSTIC STUDIES |
|---|---|---|---|---|---|---|
| Pulmonary | Airways disease | Asthma, COPD | Chest tightness, tachypnea, increased WOB | Wheezing, accessory muscle use | Increased WOB, hypoxemia, hypercapnia | Peak flow, spirometry (OVD), CXR, chest CT |
| Pulmonary | Parenchymal disease | Interstitial lung disease | Air hunger, inability to take deep breath | Dry crackles, clubbing | Increased respiratory drive, hypoxemia | Spirometry, lung volumes (RVD), chest CT |
| Pulmonary | Chest wall disease | Kyphoscoliosi s, neuromusc ular weakness | Increased WOB, inability to take deep breath | Decreased diaphragm excursion | Increased WOB | Spirometry, lung volumes (RVD), MIP/MEPs |
| Cardiac | Left heart failure | Coronary artery disease, cardi omyopathy | Chest tightness, air hunger | Wet crackles, elevated JVP | Increased WOB, hypoxemia | BNP, ECG, e chocardiogra m |
| Cardiac | Pericardial disease | Constrictive pericarditis, tamponade | Chest tightness, pulsus paradoxus | Jugular venous distention, muffled heart sounds | Increased WOB, hypoxemia | ECHO, right heart catheter ization |
| Variable | Anemia/Deco nditioning | Anemia, poor fitness | Exertional bre athlessness | Pale conjunctiva, cyanosis | Metaborecept ors, chemore ceptors | Hematocrit, metabolic panel |
6.1 Imaging¶
Chest X-ray: Hyperinflation (COPD), interstitial patterns, pleural effusions Chest CT: Interstitial lung disease, pulmonary embolism, structural abnormalities
7. MANAGEMENT & TREATMENT¶
Treatment prioritizes addressing underlying causes: 1. Pulmonary: Bronchodilators ( β -agonists, anticholinergics), corticosteroids, oxygen therapy (SpO2 ≤ 88%), pulmonary rehab 2. Cardiac: Diuretics for heart failure, vasodilators for pulmonary hypertension, anticoagulation for PE 3. Non-cardiopulmonary: Anemia management, anxiety treatment, GERD therapy 4. Symptomatic relief: Opioids (low-dose, individualized), anxiolytics (limited evidence), supplemental oxygen 5. Rehabilitation: Exercise programs (yoga, Tai Chi), remote monitoring, health coaching
7.1 Oxygen Therapy¶
Supplemental O2 for SpO2 ≤ 88% or during activity/sleep. Improves mortality in COPD with hypoxemia.
7.2 Pulmonary Rehabilitation¶
Structured exercise programs improve exercise capacity, reduce hospitalizations, and enhance quality of life in COPD and post-COVID patients.
8. PROGNOSIS & COMPLICATIONS¶
Chronic dyspnea is associated with reduced quality of life, increased hospitalizations, and mortality. Complications include deconditioning, respiratory muscle fatigue, and psychological distress (e.g., anxiety, depression). Persistent dyspnea without identifiable cause may indicate chronic breathlessness syndrome.
9. SPECIAL CONSIDERATIONS¶
Oral health: Periodontal disease, halitosis, and denture-related complications contribute to dyspnea. Post-COVID-19 syndrome is a growing cause of persistent dyspnea. Special attention to anemia, deconditioning, and psychological factors is critical.
10. KEY POINTS & CLINICAL PEARLS¶
- Use the MMRC scale for COPD dyspnea assessment.
- CPET distinguishes respiratory vs. cardiovascular dyspnea.
- Oxygen therapy improves outcomes in hypoxemic patients.
- Pulmonary rehab benefits COPD and post-COVID patients.
- Persistent dyspnea without clear cause may require specialized evaluation.
- Address reversible causes (e.g., GERD, anemia) before initiating long-term therapies.